Skip to main content
. 2023 Apr 16;11(4):852. doi: 10.3390/vaccines11040852

Table 5.

No. and type of intramuscularly delivered vaccines as second doses and no. of angioedema attacks following the vaccination (≤72 h).

Total BNT162b2 mRNA-1273 ChAdOx1-S
No. of vaccination doses (%) 203 (100%) 181 (89.2%) 18 (8.8%) 4 (2%)
No. of angioedema attacks (≤72 h) (%) 15 (100%) 12 (80%) 3 (20%) 0